BR112019004210A2 - composição farmacêutica, método e kit para tratamento da deficiência de hormônio do crescimento - Google Patents
composição farmacêutica, método e kit para tratamento da deficiência de hormônio do crescimentoInfo
- Publication number
- BR112019004210A2 BR112019004210A2 BR112019004210A BR112019004210A BR112019004210A2 BR 112019004210 A2 BR112019004210 A2 BR 112019004210A2 BR 112019004210 A BR112019004210 A BR 112019004210A BR 112019004210 A BR112019004210 A BR 112019004210A BR 112019004210 A2 BR112019004210 A2 BR 112019004210A2
- Authority
- BR
- Brazil
- Prior art keywords
- kit
- growth hormone
- hormone deficiency
- pharmaceutical composition
- treatment
- Prior art date
Links
- 206010056438 Growth hormone deficiency Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000037396 body weight Effects 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/61—Growth hormones [GH] (Somatotropin)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
composição farmacêutica, método e kit para tratamento da deficiência de hormônio do crescimento a presente invenção refere-se a uma composição, um método e um kit para o tratamento da deficiência do hormônio do crescimento. especificamente, a composição compreende uma proteína de fusão de hgh (gx-h9) e um carreador farmaceuticamente aceitável, e o método consiste na administração da proteína de fusão (gx-h9), sendo uma vez por semana, uma dose de 0,4 a 1,6 mg por kg de peso corporal de um paciente pediátrico, e uma vez a cada duas semanas, uma dose de 0,8 a 3,2 mg por kg de peso corporal de um paciente pediátrico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160110806 | 2016-08-30 | ||
| PCT/KR2017/009471 WO2018044060A1 (en) | 2016-08-30 | 2017-08-30 | PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN |
| KR1020170110161A KR20180025269A (ko) | 2016-08-30 | 2017-08-30 | hGH 융합단백질을 포함하는 성장호르몬 결핍을 치료하기 위한 약학 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019004210A2 true BR112019004210A2 (pt) | 2019-09-10 |
Family
ID=61726000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019004210A BR112019004210A2 (pt) | 2016-08-30 | 2017-08-30 | composição farmacêutica, método e kit para tratamento da deficiência de hormônio do crescimento |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190224281A1 (pt) |
| EP (1) | EP3506923B1 (pt) |
| JP (2) | JP7333519B2 (pt) |
| KR (2) | KR20180025269A (pt) |
| CN (1) | CN110177567A (pt) |
| BR (1) | BR112019004210A2 (pt) |
| CA (1) | CA3034240C (pt) |
| DK (1) | DK3506923T3 (pt) |
| ES (1) | ES2926627T3 (pt) |
| HU (1) | HUE059816T2 (pt) |
| JO (1) | JOP20190019A1 (pt) |
| PL (1) | PL3506923T3 (pt) |
| PT (1) | PT3506923T (pt) |
| RU (1) | RU2748402C2 (pt) |
| TW (4) | TW201925237A (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114874333A (zh) * | 2021-10-18 | 2022-08-09 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
| CN115845032A (zh) * | 2022-10-28 | 2023-03-28 | 深圳科兴药业有限公司 | 生长激素fc融合蛋白注射液及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4870569B2 (ja) * | 2003-11-13 | 2012-02-08 | ハンミ ホールディングス カンパニー リミテッド | 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法 |
| EP2162472B1 (en) * | 2007-05-30 | 2013-02-27 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
| US8637637B2 (en) * | 2010-01-12 | 2014-01-28 | Bill Nai-Chau Sun | Fc fusion proteins of human growth hormone |
| CA2892626A1 (en) * | 2012-12-12 | 2014-06-19 | Teva Pharmaceutical Industries Ltd. | Fusion of human growth hormone and albumin, formulation and uses thereof |
| SG11201506732YA (en) * | 2013-03-11 | 2015-09-29 | Amunix Operating Inc | Treatment of pediatric growth hormone deficiency with human growth hormone analogues |
| AU2014338575B2 (en) * | 2013-10-21 | 2019-11-07 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| WO2016079302A1 (en) * | 2014-11-21 | 2016-05-26 | Ascendis Pharma Growth Disorders Division A/S | Long-acting growth hormone dosage forms |
| WO2017142331A1 (en) * | 2016-02-17 | 2017-08-24 | Genexine, Inc. | Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency |
-
2017
- 2017-06-16 JO JOP/2019/0019A patent/JOP20190019A1/ar unknown
- 2017-08-30 CA CA3034240A patent/CA3034240C/en active Active
- 2017-08-30 DK DK17846985.4T patent/DK3506923T3/da active
- 2017-08-30 HU HUE17846985A patent/HUE059816T2/hu unknown
- 2017-08-30 TW TW108110783A patent/TW201925237A/zh unknown
- 2017-08-30 EP EP17846985.4A patent/EP3506923B1/en active Active
- 2017-08-30 CN CN201780067554.5A patent/CN110177567A/zh active Pending
- 2017-08-30 KR KR1020170110161A patent/KR20180025269A/ko not_active Application Discontinuation
- 2017-08-30 RU RU2019109154A patent/RU2748402C2/ru active
- 2017-08-30 PT PT178469854T patent/PT3506923T/pt unknown
- 2017-08-30 ES ES17846985T patent/ES2926627T3/es active Active
- 2017-08-30 PL PL17846985.4T patent/PL3506923T3/pl unknown
- 2017-08-30 TW TW109139458A patent/TWI732713B/zh active
- 2017-08-30 US US16/329,317 patent/US20190224281A1/en active Pending
- 2017-08-30 TW TW108110781A patent/TW201924714A/zh unknown
- 2017-08-30 TW TW106129474A patent/TWI718334B/zh active
- 2017-08-30 BR BR112019004210A patent/BR112019004210A2/pt unknown
- 2017-08-30 JP JP2019532910A patent/JP7333519B2/ja active Active
-
2018
- 2018-12-13 KR KR1020180161062A patent/KR102309668B1/ko active IP Right Grant
-
2023
- 2023-01-27 JP JP2023010975A patent/JP2023061978A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2926627T3 (es) | 2022-10-27 |
| CA3034240C (en) | 2024-04-23 |
| PT3506923T (pt) | 2022-09-07 |
| HUE059816T2 (hu) | 2022-12-28 |
| PL3506923T3 (pl) | 2022-11-21 |
| RU2019109154A (ru) | 2020-10-01 |
| TW201806614A (zh) | 2018-03-01 |
| KR20180025269A (ko) | 2018-03-08 |
| TWI718334B (zh) | 2021-02-11 |
| KR20180136418A (ko) | 2018-12-24 |
| CA3034240A1 (en) | 2018-03-08 |
| EP3506923A4 (en) | 2020-04-22 |
| TW202120119A (zh) | 2021-06-01 |
| EP3506923A1 (en) | 2019-07-10 |
| TWI732713B (zh) | 2021-07-01 |
| JP2019533004A (ja) | 2019-11-14 |
| TW201925237A (zh) | 2019-07-01 |
| JP2023061978A (ja) | 2023-05-02 |
| EP3506923B1 (en) | 2022-07-27 |
| KR102309668B1 (ko) | 2021-10-07 |
| JP7333519B2 (ja) | 2023-08-25 |
| CN110177567A (zh) | 2019-08-27 |
| JOP20190019A1 (ar) | 2019-02-12 |
| DK3506923T3 (da) | 2022-08-29 |
| RU2748402C2 (ru) | 2021-05-25 |
| TW201924714A (zh) | 2019-07-01 |
| US20190224281A1 (en) | 2019-07-25 |
| RU2019109154A3 (pt) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX2019012884A (es) | Terapia de combinacion. | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| MX368387B (es) | A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22. | |
| PH12015502063A1 (en) | Treatment of pediatric growth hormone deficiency with human growth hormone analogues | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| MX2021009199A (es) | Conjugado de farmaco de dos ligandos y uso del mismo. | |
| MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
| BR112014030404A2 (pt) | proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento | |
| PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| BR112019004210A2 (pt) | composição farmacêutica, método e kit para tratamento da deficiência de hormônio do crescimento | |
| MX2022013450A (es) | Formulaciones farmaceuticas. | |
| BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
| BR112012020377A8 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| JP2019529569A5 (pt) | ||
| BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
| BR112018016817A2 (pt) | composição farmacêutica e método de tratamento da deficiência do hormônio do crescimento | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| BR112022012226A2 (pt) | Métodos, método para preparar uma forma cristalina, forma cristalina, compostos e sal | |
| CY1120282T1 (el) | Φαρμακευτικη συνθεση κιτρικης σιλδεναφιλης με την μορφη ενος εναιωρηματος για εκ του στοματος χρηση | |
| PH12018500889A1 (en) | Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine | |
| BR112018002433A2 (pt) | composição farmacêutica para tratamento da enxaqueca |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |